Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Cash & Equivalents (2022 - 2025)

Neuraxis (NRXS) has disclosed Cash & Equivalents for 4 consecutive years, with $4.4 million as the latest value for Q3 2025.

  • Quarterly Cash & Equivalents rose 1577.79% to $4.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Sep 2025, up 1577.79% year-over-year, with the annual reading at $3.7 million for FY2024, 4605.79% up from the prior year.
  • Cash & Equivalents hit $4.4 million in Q3 2025 for Neuraxis, down from $6.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $6.0 million in Q2 2025 to a low of $51440.0 in Q2 2023.
  • Historically, Cash & Equivalents has averaged $1.8 million across 4 years, with a median of $761249.0 in 2023.
  • Biggest five-year swings in Cash & Equivalents: tumbled 69.03% in 2023 and later soared 4605.79% in 2024.
  • Year by year, Cash & Equivalents stood at $253699.0 in 2022, then crashed by 69.03% to $78560.0 in 2023, then skyrocketed by 4605.79% to $3.7 million in 2024, then increased by 18.4% to $4.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for NRXS at $4.4 million in Q3 2025, $6.0 million in Q2 2025, and $2.0 million in Q1 2025.